The impact of granulocyte colony-stimulating factor on quality of life in patients with severe chronic neutropenia.
Quality of life (QOL) was assessed in 10 patients receiving treatment with recombinant methionyl human granulocyte colony-stimulating factor (r-met-GCSF). The Ferrans & Powers Quality of Life Index (Cancer II) was administered at three different time points to patients with severe chronic neutropenia. Mean overall QOL increased from time 1 to time 2 from a score of 23.72 to a score of 35.93 (p = 0.006). Overall QOL was maintained throughout the study with a mean score at time 3 of 36.96 (p = 0.002). Measures on all QOL subscales, including health and functioning and socioeconomic, improved significantly. Daily therapy with r-met-GCSF significantly improves the QOL of patients with severe chronic neutropenia.
Fazio
M T
MT
Department of Medicine, UCLA School of Medicine.
Glaspy
J A
JA
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D008297:Male; D009503:Neutropenia / Q000151:congenital / Q000523:psychology / Q000628:therapy*; D011788:Quality of Life; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor